Despite these hurdles, several studies are currently in preclinical development for disorders such as facioscapulohumeral muscular dystrophy, myotonic dystrophy and centronuclear myopathy due to DNM2 mutations. This evidence concerns the gene DNM2 and centronuclear myopathy.